首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

1733211

全球糖尿病藥物市場規模：依藥物、糖尿病類型、分銷管道、區域範圍和預測

Global Diabetes Drugs Market Size By Drug (Injectable Drugs, Oral Drugs), By Diabetes Type (Type 1, Type 2), By Distribution Channel (Hospital Pharmacies, Rental Pharmacies, Online Pharmacies), By Geographic Scope and Forecast

出版日期: 2025年04月30日 | 出版商:

Verified Market Research | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄

糖尿病治療藥物市場規模及預測

2025年糖尿病藥物市場規模價值 667.2億美元，預計到2032年將達到 1,019.2億美元，2026年至2032年的年複合成長率為 6.00%。

糖尿病藥物是用來幫助糖尿病患者調節血糖值的藥物。糖尿病是一種慢性疾病，患者的身體無法產生足夠的胰島素（1 型）或對胰島素有抵抗力（2 型）。這些藥物的作用方式根據糖尿病的類型和患者的需要而有所不同。

糖尿病藥物對於幫助患者控制第1 型和第2 型糖尿病、維持正常血糖值以及降低併發症風險非常重要。抗糖尿病藥物分為幾類，包括胰島素、磺醯尿素類、Metformin以及 GLP-1 受體促效劑和 SGLT2 抑制劑等較新的療法。

由於持續的研究和技術突破，糖尿病藥物的未來前景光明。全球範圍內糖尿病盛行率的不斷上升，加上對個人化護理的日益重視，預計將推動針對特定患者需求的治療方案的發展。研究新的藥物配方和聯合治療，以提高療效並儘量減少副作用。

全球糖尿病藥物市場動態

影響全球糖尿病藥物市場的關鍵市場動態是：

關鍵市場促進因素

糖尿病盛行率上升：糖尿病盛行率上升：糖尿病越來越普遍，尤其是第2 型糖尿病，這是糖尿病藥物行業的主要驅動力。根據國際糖尿病聯盟的預測，到2045年，患有糖尿病的成年人數量將達到 7億，對有效的糖尿病治療方案的需求將日益成長。

藥物開發的進步：藥物研發的不斷進步對糖尿病藥物產業產生了重大影響。 SGLT2抑制劑、GLP-1受體促效劑、DPP-4抑制劑等創新療法的開發增加了糖尿病治療的選擇。這些新藥類別被描述為具有出色的功效和安全性，以及減肥和心血管保護等其他功效。

提高認知和篩檢計劃增加對糖尿病及其影響的了解導致了更積極的篩檢和更早期的診斷。政府計劃和醫療保健組織提高人們對糖尿病控制的必要性和早期療育的好處的認知。

主要問題

開發成本高：糖尿病藥物的研發成本特別高。這是因為疾病很複雜，需要進行大量測試才能確保安全性和有效性。開發新的糖尿病藥物需要嚴格的臨床前研究、臨床試驗和監管部門的批准，這需要多年的時間並且成本高昂。

行業競爭和定價壓力：由於存在多家現有企業和種類繁多的學名藥，糖尿病藥物行業競爭非常激烈。這種激烈的競爭給品牌藥和學名藥製造商帶來了巨大的定價壓力，這可能會影響他們的利潤率。

依從性和患者依從性：確保患者按照處方服用糖尿病藥物仍然是一個主要關注點。複雜的給藥方案、副作用以及病患教育不足都可能導致依從性差。違規可能會導致治療效果較差、醫療成本增加以及結果風險增加。

主要趨勢

更重視 GLP-1 受體促效劑：糖尿病治療產業經歷向Glucagon-Like Peptide-1（GLP-1）受體促效劑的重大轉變。這些藥物不僅有助於控制血糖值，而且還有助於減肥，因此對許多患有 2 型糖尿病的人特別有吸引力，他們中許多人都是肥胖或超重的。這些藥物的雙重益處導致配方和需求的增加。

生物相似藥的出現：隨著流行的糖尿病藥物專利到期，生物相似藥變得越來越重要。這些生物相似藥比原品牌藥便宜，為患者提供了更大的便利性。預計生物相似藥將加劇糖尿病藥物產業的競爭，降低價格，使更多患者能夠獲得重要的治療。

技術整合和數位健康解決方案：科技在糖尿病管理中的應用改變治療方法。行動應用程式、穿戴式裝置和持續血糖監測系統擴大與糖尿病藥物結合使用，以改善患者的治療效果。這些技術提供即時資料和見解，使患者和醫療保健提供者能夠就藥物變化和生活方式的改變做出更明智的決定，改善糖尿病管理。

Diabetes pharmaceuticals are medications used to help people with diabetes regulate their blood sugar levels. Diabetes is a chronic disorder in which the body either does not produce enough insulin (Type 1) or becomes resistant to insulin (Type 2). These medications act in a variety of ways depending on the kind of diabetes and the patient's requirements.

They are critical for managing both Type 1 and Type 2 diabetes assisting patients in maintaining normal blood glucose levels and lowering the risk of complications. Diabetes drugs are classified into several categories including insulin, sulfonylureas, metformin, and newer treatments such as GLP-1 receptor agonists and SGLT2 inhibitors.

The future of diabetic medications seems promising, thanks to continued research and technological breakthroughs. The rising global prevalence of diabetes combined with a growing emphasis on customized treatment is projected to result in the development of increasingly focused medications that address specific patient needs. Novel medication formulations and combination therapies are being investigated to improve efficacy while minimizing negative effects.

Global Diabetes Drugs Market Dynamics

The key market dynamics that are shaping the global diabetes drugs market include:

Key Market Drivers:

Rising Prevalence of Diabetes: Diabetes is becoming more common, particularly Type 2 diabetes which is a major driver of the diabetic medications industry. According to the International Diabetes Federation, the number of adults living with diabetes is predicted to reach 700 million by 2045 increasing the demand for effective diabetes care options.

Advancements in Medicine Development: Continuous advances in pharmaceutical research and development are having a substantial impact on the diabetic medicine industry. The development of innovative medicines such as SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors has increased the number of diabetes treatment options. These newer medication classes provide superior efficacy and safety profiles as well as additional benefits like weight loss and cardiovascular protection.

Improving Awareness and Screening Programs: Increased knowledge of diabetes and its implications is resulting in greater proactive screening and early diagnosis. Government programs and healthcare organizations are raising awareness about the necessity of diabetes control and the advantages of early intervention.

Key Challenges:

High Development Costs: Diabetes medications incur particularly high research and development (R&D) expenses due to the disease's complexity and the extensive testing required for safety and efficacy. Creating novel diabetic drugs takes rigorous preclinical research, clinical trials, and regulatory clearances which can take years and need significant financial expenditure.

Industry Competition and Pricing Pressure: The diabetic medicine industry is fiercely competitive with multiple established businesses and a variety of generic alternatives. This severe rivalry causes significant pricing pressure which can have an influence on both branded and generic medicine producers' profit margins.

Adherence and Patient Compliance: Ensuring that patients take their diabetes medications as prescribed remains a substantial concern. Complex dose regimens, adverse effects, and inadequate patient education can all contribute to low compliance rates. Noncompliance can lead to inferior treatment outcomes increased healthcare expenses, and an increased risk of consequences.

Key Trends:

Increased Focus on GLP-1 Receptor Agonists: The diabetes treatment industry is shifting significantly towards glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs not only assist control of blood sugar levels but also aid in weight loss making them especially appealing to type 2 diabetics who are frequently overweight or obese. The dual benefits of these medications have resulted in increased prescriptions and demand.

Emergence of Biosimilars: As patents for numerous popular diabetic drugs expire, biosimilars are becoming a prominent trend. These biologically comparable pharmaceuticals are less expensive than branded medications, giving patients better access. Biosimilars are projected to boost competition in the diabetic medicine industry lowering prices and allowing more patients to obtain critical therapies.

Technological Integration and Digital Health Solutions: The use of technology in diabetes management is transforming treatment techniques. Mobile apps, wearable gadgets, and continuous glucose monitoring systems are increasingly being used with diabetes medications to improve patient results. These technologies give real-time data and insights allowing patients and healthcare providers to make more educated decisions about medication modifications and lifestyle changes resulting in improved diabetes management.

Global Diabetes Drugs Market Regional Analysis

Here is a more detailed regional analysis of the global diabetes drugs market:

North America:

The North American diabetes medicine industry is primarily driven by the rising prevalence of diabetes and obesity as well as an aging population and sedentary habits. This supremacy stems partly from the region's advanced healthcare infrastructure, high healthcare spending, and the presence of big pharmaceutical companies that invest extensively in diabetes research and treatment development. According to the Centers for Disease Control and Prevention (CDC), an estimated 37.3 million Americans (11.3% of the population) will have diabetes by 2023, with another 96 million individuals suffering from prediabetes.

The market is also being driven by technical developments in drug delivery systems and the growing acceptance of innovative diabetes care regimens. The United States Food and Drug Administration (FDA) authorized five new diabetic medications in 2023, demonstrating the field's continued innovation. Furthermore, the National Institutes of Health (NIH) has committed $1.2 billion for diabetes research in fiscal year 2023, demonstrating the government's commitment to addressing this health epidemic.

Asia Pacific:

The Asia Pacific region is seeing the highest growth in the diabetes medications market owing to a rapidly growing diabetic population and improved healthcare infrastructure. This fast growth is fueled by changing lifestyles, urbanization, and rising obesity rates, particularly in China and India. According to the International Diabetes Federation (IDF), the number of diabetic people in the Western Pacific region, which includes much of Asia, is anticipated to climb by 46%, from 163 million in 2021 to 238 million by 2045.

The Asian Development Bank (ADB) expects Asia's GDP to grow by 4.8% in 2024, with many countries investing considerably in healthcare facilities. According to the World Bank, China's healthcare expenditure will account for 6.5% of its GDP in 2020, up from 4.5% in 2000. India's National Health Policy seeks to raise public health spending to 2.5% of GDP by 2025. The increase in disposable income is also contributing to higher healthcare costs. According to the World Bank, GDP per capita in East Asia and the Pacific has improved from $1,957 in 2000 to $11,487 in 2021, allowing for better access to diabetes drugs.

Global Diabetes Drugs Market: Segmentation Analysis

The Global Diabetes Drugs Market is segmented based on Drug, Diabetes Type, Distribution Channel, and Geography.

Diabetes Drugs Market, By Drug

Injectable Drugs
Oral Drugs
Insulins
Others

Based on the Drug, the Global Diabetes Drugs Market is bifurcated into Injectable Drugs, Oral Drugs, Insulins, and Others. The insulin segment dominates the global diabetes drugs market due to its essential role in managing blood sugar levels for individuals with Type 1 and advanced Type 2 diabetes. Insulin therapy is critical for patients who cannot produce adequate insulin naturally making it a cornerstone of diabetes management. The increasing prevalence of diabetes worldwide, particularly in the Asia Pacific and North America drives the demand for insulin products. Additionally, advancements in insulin formulations and delivery methods such as pen devices and continuous glucose monitors enhance patient adherence and treatment outcomes.

Diabetes Drugs Market, By Diabetes Type

Type 1
Type 2

Based on the Diabetes Type, the Global Diabetes Drugs Market is bifurcated into Type 1, and Type 2. The Type 2 diabetes segment dominates the global diabetes drugs market, primarily due to the higher prevalence of this condition compared to Type 1 diabetes. Type 2 diabetes accounts for approximately 90-95% of all diabetes cases, largely driven by rising obesity rates, sedentary lifestyles, and an aging population. The increased focus on lifestyle management including weight loss and dietary changes further propels demand for various therapeutic options. Additionally, advancements in treatment options such as oral medications and injectable therapies, specifically targeting Type 2 diabetes enhance the segment's growth.

Diabetes Drugs Market, By Distribution Channel

Hospital Pharmacies
Rental Pharmacies
Online Pharmacies
Others

Based on the Distribution Channel, the Global Diabetes Drugs Market is bifurcated into Hospital Pharmacies, Rental Pharmacies, Online Pharmacies, and Others. The dominant distribution channel in the global diabetes drugs market is hospital pharmacies. This is primarily due to their critical role in managing diabetes care where healthcare professionals closely monitor and provide medications to patients with complex needs. Hospital pharmacies often offer a wide range of diabetes medications including insulin and oral hypoglycemic agents ensuring that patients receive appropriate treatment during their hospital stay. Additionally, hospital pharmacies are integral in providing patient education and personalized medication management which is vital for diabetes control.

Diabetes Drugs Market, By Geography

North America
Europe
Asia Pacific
Rest of the World

Based on Geography, the Global Diabetes Drugs Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. The North American region dominates the global diabetes drugs market primarily due to its advanced healthcare infrastructure, high prevalence of diabetes, and significant investments in research and development. The United States accounts for a substantial share of the market driven by a growing aging population and increasing rates of obesity which contribute to the rising incidence of diabetes.

Key Players

The "Global Diabetes Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Novo Nordisk, Biocon, AstraZeneca, Sanofi, BoehringerIngelheim, Eli Lilly, Johnson & Johnson, Pfizer, and Bristol Myers Squibb.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Diabetes Drugs Market Key Developments

In January 2024, Glenmark Pharmaceuticals Ltd. released Lirafit, a biosimilar to the anti-diabetic medication Liraglutide, in India. The daily cost of this medicine is around USD 1.21 for a normal dose of 1.2 mg.
In June 2023, Pfizer, Inc. said that it would continue clinical development of its oral GLP-1-RA candidate for the treatment of adults with type 2 diabetes and obesity.
March 2023 - The Central Drugs Standard Control Organization (CDSCO) in India granted Sanofi (India) a marketing license for their diabetes medicine Soliqua.

1 INTRODUCTION OF GLOBAL DIABETES DRUGS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL DIABETES DRUGS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL DIABETES DRUGS MARKET, BY DRUG

5.1 Overview
5.2 Injectable Drugs
5.3 Oral Drugs
5.4 Insulins
5.5 Others

6 GLOBAL DIABETES DRUGS MARKET, BY DIABETES TYPE

6.1 Overview
6.2 Type1
6.3 Type 2

7 GLOBAL DIABETES DRUGS MARKET, BY DISTRIBUTION CHANNEL

7.1 Overview
7.2 Hospital Pharmacies
7.3 Rental Pharmacies
7.4 Online Pharmacies
7.5 Others

8 GLOBAL DIABETES DRUGS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East And Africa

9 GLOBAL DIABETES DRUGS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Novo Nordisk
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 AstraZeneca
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Biocon
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Sanofi
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Eli Lilly
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Johnson & Johnson
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Bristol Myers Squibb
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 BoehringerIngelheim
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Pfizer
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments